Insomnia: 2 a.m. wakefulness, hyperarousal, circadian misalignment, and evidence-based treatment strategies

Insomnia is a prevalent sleep-wake disorder characterized by difficulty initiating sleep, maintaining sleep, or experiencing non-restorative sleep, with daytime impairment (fatigue, cognitive dysfunction, mood disturbance, or reduced performance). Although many people experience transient sleeplessness, persistent insomnia disorder typically involves a chronic pattern—often lasting at least three months—shaped by physiological hyperarousal, cognitive factors, and circadian rhythm disruption.

A key mechanism is hyperarousal of the nervous system. During normal sleep onset, cortical activity and autonomic arousal decrease, allowing thalamocortical networks and sleep-promoting systems to coordinate slow-wave sleep and, later, REM sleep. In insomnia, this “arousal brake” is less effective: heart rate variability may indicate heightened sympathetic tone, stress-responsive systems (including the HPA axis) can be more reactive, and cortical networks may remain in a state of heightened vigilance. This can make the transition to sleep feel effortful, even when the person is in bed with adequate opportunity for sleep.

Cognitive arousal often co-travels with physiological hyperarousal. A well-described pattern is sleep-preoccupation: in bed, the individual monitors time and predicts negative outcomes (“If I don’t sleep now, tomorrow will be ruined”). Such threat-based appraisals intensify attentional focus and maintain wakefulness. This is reinforced by classical conditioning: the bed, bedroom, and nighttime routine become cues for wakefulness when sleep does not occur. The result is a self-perpetuating loop—greater effort and worry lead to more arousal, which further delays sleep.

Circadian misalignment also plays a central role. Sleep timing is governed by the circadian pacemaker in the suprachiasmatic nucleus, synchronized by light exposure (especially morning light), meal timing, temperature rhythms, and social schedules. Evening light from screens, irregular sleep/wake times, and late caffeine can shift circadian phase later, causing the biological night to arrive after the person attempts to sleep. Even if the person feels sleepy, circadian delay can prevent sleep propensity from rising at the intended bedtime.

Behavioral factors commonly contribute: inconsistent schedules, extended time in bed while awake, irregular naps, and use of alcohol or nicotine can fragment sleep architecture. Alcohol may initially sedate, but it typically suppresses REM sleep early and promotes awakenings later in the night. Sedating antihistamines or certain medications can also alter sleep continuity and cause next-day effects that further impair sleep confidence.

Diagnostic evaluation focuses on the insomnia phenotype and exclusion of secondary causes. Clinicians assess sleep history, total sleep time, sleep latency, awakenings, and functional consequences. It is also critical to screen for comorbidities such as anxiety disorders, depressive disorders, PTSD, substance use, restless legs syndrome, periodic limb movements, obstructive sleep apnea, and painful or medical conditions. Because these conditions can drive insomnia, treating the underlying driver often improves sleep outcomes.

The most evidence-supported first-line therapy is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I targets the mechanisms above: stimulus control (e.g., using the bed only for sleep and sex, leaving the bed if unable to sleep), sleep restriction therapy (increasing sleep efficiency by limiting time in bed to consolidate sleep, then gradually expanding), cognitive restructuring (reducing catastrophic beliefs about wake time), and relaxation or arousal-management strategies (breathing techniques, progressive muscle relaxation). CBT-I improves both sleep continuity and insomnia-related beliefs, with benefits that often persist beyond treatment.

Pharmacotherapy may be considered for short-term relief or as adjunctive treatment, particularly when rapid symptom control is needed. Options include non-benzodiazepine hypnotics, certain melatonin receptor agonists, and other agents depending on patient risk and comorbidities. However, medications can carry risks such as next-day sedation, cognitive impairment, tolerance, dependence, and adverse effects (especially in older adults). Clinicians typically recommend using the lowest effective dose for the shortest duration and pairing medication with CBT-I when possible.

A practical night-to-night strategy begins with reducing time awake in bed and minimizing arousal triggers. Consistent wake time, morning light exposure, and limiting late caffeine can strengthen circadian alignment. Evening wind-down routines, dimming lights, avoiding emotionally activating content before bed, and managing stress during the day reduce evening hyperarousal. If wakefulness occurs at night, brief, low-stimulation activities (e.g., reading non-stimulating material in dim light) can help recondition the brain away from “bed equals wake.”

Finally, clinicians emphasize that insomnia is not simply “laziness” or a lack of willpower; it is a disorder of arousal, cognition, and timing. Understanding the biological and psychological mechanisms behind 2 a.m. wakefulness provides a pathway to targeted interventions and durable recovery.

Source: @BalogunSonia4